Medical & Diagnostic Laboratories
The industry — Medical and diagnostic laboratories
Base industry report for 621510 →- Establishments · CanadaA
- 2,470
- Under 10 employeesA
- 65%
Of 2,470 Canadian establishments with employees, 65% have fewer than ten — mostly small operators.
Entry signal — what decides who wins here
One thing must be trueEntry turns on a single condition that can be named and tested before much is spent. Clear it and this becomes an execution question; fail it and no amount of operating skill helps.
Raise or borrow the entry ticket, or buy an operator who has already paid it. The barrier is money rather than permission, so it yields to a balance sheet — and an acquisition is usually cheaper than a start.
Measured, not forecast: the share of US establishments opening in one year that were still active later. It counts good operators and bad ones together, which is exactly why it is the honest answer to “what are the odds”. It is for the whole sector rather than this market, and the ten-year figure comes from an older cohort because no younger one has reached ten years.
This is not a probability of success, and it is not a verdict on you. No survival probability is published per market, and inventing one would be worse than saying so. What the bar reads is how much of the outcome sits inside an operator's control: green means the hurdles are ones a better operator clears, red means the binding constraint is capital, an asset or a permission rather than execution. Someone arriving with an advantage this screen did not assume can win a market shown in red.
Companies named in this market · 4
The binding constraint — entry cost + regulatory drag
Largest angel cluster after software — 99 companies across AB/ON/QC. Cut because Health Canada / FDA pathways, reimbursement dependency and 3–7 year clinical validation cycles put first revenue outside any window a small entrant can fund. The angel concentration here is a warning, not an invitation: it means the patient capital is already committed.
Specimens move by courier on a fixed schedule, so a lab serves the area its couriers can reach within the sample's viability window. Reimbursement is provincial. Both boundaries are regional, not national.
Handle — What the largest Canadian network cost, against how much testing it does. Quest's filing states both sides of the LifeLabs deal in the same document: the price paid and, a year later, the requisition volume and site count it bought. That gives a Canadian entrant the two numbers it cannot get anywhere else — what a collection footprint is worth and how much throughput sits behind it.
C$1.35B divided by the 'over 350' collection centres and by the approximately 23 million requisitions stated in Quest's FY2025 10-K. Both are upper bounds: the price also bought about 15 laboratories, a courier fleet and a digital-health business, so attributing the whole enterprise to the collection footprint overstates what one centre alone is worth. The requisition count is 2025, a year after the deal closed.
Sectors joined: Diagnostics · Diagnostics/Biotech · Biotech Diagnostics · PCR Diagnostics · Healthtech - Ophthalmic Diagnostics
[UNVERIFIED] Sector-to-NAICS mapping is analyst judgment — see data/angel-sector-map.json. Counts are a per-record cross-reference and are not additive across records.
Who you would be competing with
The operators already at scale here, and whoever is buying these businesses. In most of these industries the competition an entrant meets is local, so this is who sets the terms rather than a list of everyone in the trade.
Financials & market size — sourced
Figures that came from a filing, a results release or reputable reporting, each carrying its evidence tier.
Market size, derived
Built from the competitor set upward rather than quoted from a forecast. Published TAMs in these categories are frequently reverse-engineered from each other, so any published figure is checked against the vendor arithmetic rather than trusted on its own.
Disclosed revenue from 1 of 4 named vendors. The market is at least this large.
No vendor has both a disclosed revenue and a published share.
Only a revenue floor is known — the true market is larger by whatever the undisclosed vendors earn.
Competitor set · 4 named · 1 disclose revenue
| Name | Revenue | Share | Note |
|---|---|---|---|
| Quest DiagnosticsNYSE: DGXA | $11.0B | — | FY2025 net revenues, from the 10-K filed 26 February 2026 |
| LifeLabsA | not disclosed | — | Bought by Quest for approximately C$1.35B in August 2024; about 15 laboratories, over 350 collection centres in BC, Ontario and Saskatchewan and roughly 23 million requisitions in 2025. Quest does not report its revenue separately |
| Dynacare (Labcorp)C | not disclosed | — | The other national community-laboratory brand in Canada; Labcorp does not disclose a Canadian figure and its filings were not opened for this record |
| Provincial hospital and public-health laboratory systemsC | not disclosed | — | Hold most of the testing volume in most provinces and are the payer's own capacity rather than a contestable market; no provincial series of laboratory spending was obtained |
Evidence
Evidence. The LifeLabs purchase price, its laboratory and collection-centre counts, its 2025 requisition volume, Quest's FY2025 net revenues and the revenue-per-requisition series were all read from Quest Diagnostics' Form 10-K for the year ended 31 December 2025, as filed on EDGAR on 26 February 2026 — the price from the business-combinations note and the revenue series from the results-of-operations table, not from headline bullets [A]. Establishment counts and size bands are Statistics Canada, December 2023 [A]; no US County Business Patterns figures joined for this six-digit code. What was not sourced: any Canadian revenue, funding-envelope or fee-schedule figure. Labcorp's Canadian arm Dynacare publishes nothing that was opened; no provincial count of licensed community laboratories or specimen-collection centres was obtained, and whether a province will issue a new community-laboratory licence at all was not verified against any statute — it is the question a full study would have to answer first. The reading that public and hospital laboratories hold most of the volume outside LifeLabs' three provinces is inference, not measurement. The cut factor — that Health Canada and FDA pathways, reimbursement dependency and multi-year validation cycles put first revenue outside a small entrant's funding window — is analyst judgment and applies to the diagnostics-developer reading of this code; the operating-laboratory reading is cut by the same licence and payer structure from the other direction.
Where the industry talks
The associations, forums and events where people in this trade actually talk shop — where to listen before entering, and where the first customers are found. Each link was opened on the date shown.
Members: site says its job bank 'reaches over 14,500 members'; the national certifying body for medical laboratory technologists and assistants.
CSMLS's annual national medical laboratory conference.
Ontario association (formerly OSMT); site cites 15,000+ lab professionals in Ontario, which is the workforce rather than a stated member count. Runs an Annual Lab Summit (mlpao.org/annual-lab-summit-2027).
Association of commercial clinical laboratory companies (Quest, Labcorp and peers); the operator-side lobby. No member count stated.
Clinical chemists and lab directors; runs online forums, scientific divisions and the Laborastories podcast (myadlm.org/community/podcast). No member count stated.
The largest clinical laboratory conference and equipment expo in North America; next edition ADLM 2027.
College of American Pathologists' monthly on clinical lab tests, instruments, management and regulation.
News briefing for clinical laboratory and pathology executives (companion to The Dark Report).
r/medlabprofessionals is the busy practitioner subreddit but neither its RSS feed nor search would confirm it from this network, so it is not listed. ASCP (ascp.org) blocked automated access and is left off in favour of ADLM.
Software serving this industry
Vertical software markets filed along the same branch of NAICS — who sells to these businesses, and who an entrant would have to displace.
Software attached to imaging hardware — the same razor-and-blade structure that decided the veterinary study, with a regulatory floor on top: PACS and any diagnostic AI are regulated medical devices requiring FDA clearance or Health Canada licensing. Capital and clearance timelines both sit outside a small entrant's runway. Sourced update: the money in this market is in the scanners, not the software. GE HealthCare's imaging line alone is $9.24B and Philips' Diagnosis & Treatment €8.5B, while the leading independent imaging-IT vendor, Sectra, turns over roughly a tenth of that — and its growth is in cloud recurring revenue, up 49%.
What this category is. The back office between a care provider and whoever pays: eligibility checks, claims and the clearinghouse that carries them, coding, denials and appeals, payer-to-provider payments, patient statements and collections, and the credentialing and enrolment that let a clinician bill a plan at all. The coded customer is ambulatory care (621): physician groups, clinics, labs and home health. But the largest buyers of several segments are hospitals and health systems (outsourced revenue cycle, inpatient coding) and health plans (payer payments, provider data, credentialing). How it differs from the neighbouring records. Electronic health records and practice management (6211) sells the chart and scheduling; athenahealth appears here only for its revenue-cycle business, and its funding is not re-researched. EHR+ patient engagement (6211) sells the portal and intake. Patient booking (6211) sells patient acquisition. HIPAA compliance (6211) sells security and audit. Medical imaging (621510) sells PACS. This record is the money and paperwork layer. Who owns the rails. Optum completed its combination with Change Healthcare on 3 October 2022 [A, Optum]. The February 2024 ransomware attack on Change touched about 192.7 million individuals, the largest US healthcare breach on record [B, CyberInsider citing the HHS OCR filing], and stopped claims for providers across the country. That shows how much of the network runs through one company. Availity says it connects over two million providers to every US health plan and handles over 13 billion transactions a year; its shareholders include Anthem (Elevance), Humana, HCSC and GuideWell, and Novo Holdings bought Francisco Partners' stake in July 2021 [A, Novo Holdings]. Waystar (Nasdaq: WAY) earned $1,099M of revenue in 2025, up 17%, from about 30,000 clients representing over 1 million providers [A, Waystar release]. Experian Health sells patient access, eligibility and identity inside Experian plc. Zelis runs the payer-to-provider payment side: 725 payer clients, 850K+ providers and $300B+ of payment volume by its own count [C]. Bain Capital and Parthenon sold a minority stake to a Mubadala-led group that closed on 26 November 2024 [A, Kirkland & Ellis]; the reported $17B valuation is Bloomberg's, not opened here. Who owns the outsourced work. R1 RCM was taken private by TowerBrook and CD&R at about $8.9B, closing 19 November 2024 [A, CD&R]. Ensemble Health Partners began as Bon Secours Mercy Health's revenue-cycle arm; Golden Gate Capital bought 51% in 2019 in a deal reported at about $1.2B [B, Becker's]. athenahealth, bought by Bain Capital and Hellman & Friedman for $17B [B, Healthcare Dive], bundles billing with its ambulatory record. The AI wave is already funded. AKASA (inpatient coding for 500 hospitals, by its own count) raised a $60M Series B led by BOND in 2021 [A]. Adonis raised a $40M Series C led by Quadrille Capital in March 2026, over $95M in total, and claims more than 4x revenue growth in 2025 [A, company release]. Candid Health raised a $52.5M Series C led by Oak HC/FT, $99.5M in total [B, HLTH]. Infinitus raised a $51.5M Series C led by Andreessen Horowitz, $102.9M in total, for AI agents that call payers [B, Pulse 2.0]. In credentialing, Medallion has raised $130M (latest $43M led by Acrew Capital, August 2025) and has acquired Andros [A]. CertifyOS raised a $40M Series B led by Transformation Capital in June 2025 [A]. Uno Health (Medicaid and benefits enrolment) was bought by Findhelp in October 2025 [B]. Canada. Provincial plans pay physicians, so the US claims-and-denials problem mostly does not exist. Billing is bundled with the record: more than 40,000 Canadian health professionals use a TELUS Health EMR [A, TELUS], and TELUS's CHR files OHIP claims through MDBilling [A, TELUS help centre]. mdbilling.ca now redirects to Dr.Bill, which claims 13,000+ physicians across OHIP, MSP and AHCIP [C]. TELUS eClaims covers direct billing to private insurers for allied health. Why a newcomer cannot get in. The clearinghouse and payment rails are owned by Optum, Availity (owned by payers), Waystar and Zelis. Each depends on connections to thousands of payers and on volume pricing. The outsourced hospital work is owned by private-equity platforms worth billions. Every point task an AI startup might attack (coding, denials, payer calls, credentialing, patient billing) already has a venture-backed player with $50M–$130M raised, and the incumbents are buying or building the same AI. Waystar's acquisition of Iodine is one example. In Canada the pain is small and the record vendors bundle it. Incumbent vulnerability decides it.